Đăng xuất
Augmentin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.
Short-term treatment of bacterial infections at the following sites when caused by amoxicillin-clavulanate-susceptible organisms:
Upper respiratory tract infections (including ENT) eg, recurrent tonsillitis, sinusitis, otitis media, typically caused by Streptococcus pneumoniae, Haemophilus influenzae#, Moraxella catarrhalis# and Streptococcus pyogenes.
Lower respiratory tract infections eg, acute exacerbations of chronic bronchitis, lobar and bronchopneumonia, typically caused by Streptococcus pneumoniae, Haemophilus influenzae# and Moraxella catarrhalis#.
Genitourinary tract infections eg, cystitis, urethritis, pyelonephritis, female genital infections typically caused by Enterobacteriaceae* (mainly Escherichia coli#), Staphylococcus saprophyticus and Enterococcus spp and gonorrohoea caused by Neisseria gonorrhoeae#.
Skin and soft tissue infections typically caused by Staphylococcus aureus#, Streptococcus pyogenes and Bacteroides spp#.
Bone and joint infections eg, osteomyelitis typically caused by Staphylococcus aureus#, where more prolonged therapy may be appropriate.
Other Infections eg, septic abortion, puerperal sepsis, intra-abdominal sepsis.
#Some members of these species of bacteria produce β-lactamase, rendering them insensitive to amoxicillin alone (see Pharmacology: Pharmacodynamic under action).
Susceptibility to Augmentin will vary with geography and time. Local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary.
Infections caused by amoxicillin-susceptible organisms are amenable to Augmentin treatment due to its amoxicillin content. Mixed infections caused by amoxicillin-susceptible organisms in conjunction with amoxicillin-clavulanate-susceptible β-lactamase-producing organisms may therefore be treated by Augmentin.
